ArticleInternational journal of breast cancer2025

Clinical Outcomes of HER2-Low Versus HER2-Zero in HR-Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study.

Thiti Susiriwatananont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.